Literature DB >> 16547389

Multiplicity of mammalian reductases for xenobiotic carbonyl compounds.

Toshiyuki Matsunaga1, Shinichi Shintani, Akira Hara.   

Abstract

A variety of carbonyl compounds are present in foods, environmental pollutants, and drugs. These xenobiotic carbonyl compounds are metabolized into the corresponding alcohols by many mammalian NAD(P)H-dependent reductases, which belong to the short-chain dehydrogenase/reductase (SDR) and aldo-keto reductase superfamilies. Recent genomic analysis, cDNA isolation and characterization of the recombinant enzymes suggested that, in humans, the six members of each of the two superfamilies, i.e., total of 12 enzymes, are involved in the reductive metabolism of xenobiotic carbonyl compounds. They comprise three types of carbonyl reductase, dehydrogenase/reductase (SDR family) member 4, 11beta-hydroxysteroid dehydrogenase type 1, L-xylulose reductase, two types of aflatoxin B1 aldehyde reductase, 20alpha-hydroxysteroid dehydrogenase, and three types of 3alpha-hydroxysteroid dehydrogenase. Accumulating data on the human enzymes provide new insights into their roles in cellular and molecular reactions including xenobiotic metabolism. On the other hand, mice and rats lack the gene for a protein corresponding to human 3alpha-hydroxysteroid dehydrogenase type 3, but instead possess additional five or six genes encoding proteins that are structurally related to human hydroxysteroid dehydrogenases. Characterization of the additional enzymes suggested their involvement in species-specific biological events and species differences in the metabolism of xenobiotic carbonyl compounds.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16547389     DOI: 10.2133/dmpk.21.1

Source DB:  PubMed          Journal:  Drug Metab Pharmacokinet        ISSN: 1347-4367            Impact factor:   3.614


  26 in total

1.  Roles of rat and human aldo-keto reductases in metabolism of farnesol and geranylgeraniol.

Authors:  Satoshi Endo; Toshiyuki Matsunaga; Chisato Ohta; Midori Soda; Ayano Kanamori; Yukio Kitade; Satoshi Ohno; Kazuo Tajima; Ossama El-Kabbani; Akira Hara
Journal:  Chem Biol Interact       Date:  2010-12-25       Impact factor: 5.192

2.  Proteomic analysis of cell lines to identify the irinotecan resistance proteins.

Authors:  Xing-Chen Peng; Feng-Ming Gong; Meng Wei; Xi Chen; Ye Chen; Ke Cheng; Feng Gao; Feng Xu; Feng Bi; Ji-Yan Liu
Journal:  J Biosci       Date:  2010-12       Impact factor: 1.826

3.  Reductive metabolism of nabumetone by human liver microsomal and cytosolic fractions: exploratory prediction using inhibitors and substrates as marker probes.

Authors:  Kaori Matsumoto; Tetsuya Hasegawa; Junichi Koyanagi; Tamiko Takahashi; Masayuki Akimoto; Kenji Sugibayashi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2015-06       Impact factor: 2.441

4.  Metabolism of bupropion by carbonyl reductases in liver and intestine.

Authors:  Jamie N Connarn; Xinyuan Zhang; Andrew Babiskin; Duxin Sun
Journal:  Drug Metab Dispos       Date:  2015-04-22       Impact factor: 3.922

5.  Oxylipin profiling of human plasma reflects the renal dysfunction in uremic patients.

Authors:  Da-Yong Hu; Ying Luo; Chang-Bin Li; Chun-Yu Zhou; Xin-Hua Li; Ai Peng; Jun-Yan Liu
Journal:  Metabolomics       Date:  2018-08-01       Impact factor: 4.290

Review 6.  Metabolite damage and its repair or pre-emption.

Authors:  Carole L Linster; Emile Van Schaftingen; Andrew D Hanson
Journal:  Nat Chem Biol       Date:  2013-02       Impact factor: 15.040

Review 7.  Bioanalysis of eukaryotic organelles.

Authors:  Chad P Satori; Michelle M Henderson; Elyse A Krautkramer; Vratislav Kostal; Mark D Distefano; Mark M Distefano; Edgar A Arriaga
Journal:  Chem Rev       Date:  2013-04-10       Impact factor: 60.622

8.  Mitigating the Metabolic Liability of Carbonyl Reduction: Novel Calpain Inhibitors with P1' Extension.

Authors:  Andreas Kling; Katja Jantos; Helmut Mack; Wilfried Hornberger; Gisela Backfisch; Yanbin Lao; Marjoleen Nijsen; Beatrice Rendenbach-Mueller; Achim Moeller
Journal:  ACS Med Chem Lett       Date:  2018-02-04       Impact factor: 4.345

9.  Effects of Phenelzine Administration on Mitochondrial Function, Calcium Handling, and Cytoskeletal Degradation after Experimental Traumatic Brain Injury.

Authors:  Rachel L Hill; Indrapal N Singh; Juan A Wang; Edward D Hall
Journal:  J Neurotrauma       Date:  2018-12-12       Impact factor: 5.269

10.  Structural basis for substrate specificity in human monomeric carbonyl reductases.

Authors:  Ewa S Pilka; Frank H Niesen; Wen Hwa Lee; Yasser El-Hawari; James E Dunford; Grazyna Kochan; Vladimir Wsol; Hans-Joerg Martin; Edmund Maser; Udo Oppermann
Journal:  PLoS One       Date:  2009-10-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.